Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.42 |
| ▸ | NISCH | Q9Y2I1 | 3/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23661740 | 0.87 | ESR1 (0.37) | ESR1ESR2 | |
| SCHEMBL18934316 | 0.82 | MAOA (0.43) | MAOAMAOBNISCHNR3C2TAAR1 | |
| SCHEMBL22725661 | 0.81 | TSHR (0.38) | ALDH1A1 | |
| SCHEMBL20756637 | 0.81 | ESR1 (0.36) | ESR1ESR2 | |
| SCHEMBL21186473 | 0.80 | ESR1 (0.35) | ESR1ESR2 | |
| SCHEMBL18559669 | 0.79 | NOS3 (0.35) | ESR1 | |
| SCHEMBL22222009 | 0.79 | ALDH1A1 (0.35) | ALDH1A1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL21653566 | 0.78 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL19919582 | 0.76 | APLNR (0.36) | ESR1ESR2 | |
| SCHEMBL23661913 | 0.76 | CXCR4 (0.34) | GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170121328-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121328-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | MAOA 1841/4885MAOB 408/4885NISCH 3124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.